Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07020611

First-In-Human Study Evaluating Aneurysm Sac Lining in AAA Patients

The goal of this clinical trial is to evaluate the safety and feasibility of the Cygnum Aneurysm Sac Management Device in patients with abdominal aortic aneurysms treated with endovascular aneurysm repair (EVAR). The main questions it aims to answer are:

1. Is the Cygnum device safe when used adjunctively with standard EVAR endografts? 2. Does it effectively reduce or prevent type II endoleaks by managing the aneurysm sac?

Participants will:

1. Undergo EVAR with adjunctive implantation of the Cygnum device 2. Have follow-up imaging (e.g., CT scans) and clinical assessments to evaluate device position and sac behavior over time

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient can understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent
  • Patient is willing to complete the follow-up according to the requirements of the protocol.
  • Patient AAA anatomy complies with "instructions for use" for commercial EVAR devices used
  • ≥18 years old
  • Abdominal aortic aneurysm with sac diameter ≥ 5.5cm in males and ≥ 5.0cm in females
  • Maximum blood flow luminal diameter ≤ 50mm
  • Eligible for endovascular aneurysm repair based on anatomical considerations, such as adequate iliac/femoral access
  • Patient is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive.

Exclusion criteria

  • Concomitant Common Iliac Artery aneurysms ≥ 25mm
  • Life expectancy <2 years
  • Already participating in an investigational drug or device study
  • Known allergy or contraindication to any study device material
  • Coagulopathy or uncontrolled bleeding disorder
  • Ruptured, leaking, inflammatory or mycotic aneurysm
  • Connective tissue diseases (e.g., Marfan Syndrome)
  • Unsuitable vascular anatomy that may interfere with device introduction or deployment, in the opinion of the investigator
  • Aneurysmal or dissected disease of the descending thoracic aorta
  • Previous surgical or EVAR repair for AAA
  • Myocardial infarction and/or major heart surgery ≤ 90 days prior to the procedure
  • Transient Ischemic Attack or stroke ≤ 90 days prior to the procedure
  • Unstable angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia or valvular disease ≤ 30 days prior to the procedure
  • Unable or unwilling to comply with study follow-up requirements
  • Serum creatinine level ≥ 180 µmol/L
  • Patients of childbearing potential who are pregnant or planning to become pregnant during the course of the study
  • Patient has other medical, social or psychological problems that, in the opinion of the investigator, study involvement would not be in their best interest.

Treatment and study plan

Cygnum Aneurysm Sac Management Device (ASMD)

Device

Cygnum ASMD, adjunctive to EVAR, lines the aneurysmal wall to prevent type II endoleaks

Primary outcomes

  1. Incidence of major adverse events (MAEs)

    Time frame: 30 days post-procedure

    Rate of related major adverse events (MAEs)

  2. Procedural Technical Success

    Time frame: Immediately after the intervention

    Technical success, defined as lining the AAA sac wall with the investigational devices

Secondary outcomes

  1. Incidence of related major adverse events (MAEs)

    Time frame: 12 months post procedure

    Incidence rate of related major adverse events (MAEs)

  2. Incidence of related serious adverse events (SAEs)

    Time frame: 12 months post procedure

    Incidence rate of related serious adverse events (SAEs)

  3. Efficacy - Type II endoleaks

    Time frame: 12 months post procedure

    Incidence of type II endoleaks

  4. Efficacy - AAA sac diameter

    Time frame: 12 months post procedure

    Change in AAA sac diameter

Study contacts

Contact information is provided by the study sponsor or research team.

Raja N Ghanem

CONTACT

[email protected]

612-840-2723

Sponsors and collaborators

Lead sponsor

Life Seal Vascular Inc.

Industry

Collaborators

  • Auckland City Hospital

Registry information

Official study title

Aneurysm SaC ManagemENt Device for Abdominal Aortic Aneurysms First-in-Human (ASCEND) Study

Acronym: ASCEND

Important dates

Study start
2025
Primary completion
2026
Study completion
2028
First posted
Jun 13, 2025
Registry last updated
Dec 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.